David P. Bonita - Jun 6, 2024 Form 4 Insider Report for Third Harmonic Bio, Inc. (THRD)

Role: Director
Signature: /s/ Christopher Murphy, Attorney-in-Fact
Stock symbol: THRD
Transactions as of: Jun 6, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/10/2024, 04:20 PM
Previous filing: Sep 21, 2023
Next filing: Jun 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	THRD	Director Stock Option (right to buy)	Award	$0	+20K		$0.00	20K	Jun 6, 2024	Common Stock	20K	$13.85	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option will vest in full on the earlier of (a) June 6, 2025 and (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F2	Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Content

The option will vest in full on the earlier of (a) June 6, 2025 and (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.